Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Lisocabtagene maraleucel|
JCAR017 comprises equal amount of CD4+ and CD8+ autologous T lymphocytes engineered to express chimeric antigen receptors containing an anti-CD19 fragment fused to the 4-1BB (CD137) signaling domain, which may results in immune modulating and anti-tumor activities (PMID: 32888407).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Lisocabtagene maraleucel||Breyanzi||JCAR 017|JCAR017|JCAR-017||Breyanzi (lisocabtagene maraleucel) comprises equal amount of CD4+ and CD8+ autologous T lymphocytes engineered to express chimeric antigen receptors containing an anti-CD19 fragment fused to the 4-1BB (CD137) signaling domain, which may results in immune modulating and anti-tumor activities (PMID: 32888407). Breyanzi (lisocabtagene maraleucel) is FDA approved for use in patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02631044||Phase I||Lisocabtagene maraleucel||Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)||Recruiting||USA||0|
|NCT03331198||Phase Ib/II||Lisocabtagene maraleucel Ibrutinib + Lisocabtagene maraleucel||Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)||Recruiting||USA||0|
|NCT04245839||Phase II||Lisocabtagene maraleucel Cyclophosphamide + Fludarabine||A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)||Recruiting||USA | CAN||8|
|NCT03483103||Phase II||Lisocabtagene maraleucel||Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)||Active, not recruiting||USA||0|
|NCT03484702||Phase II||Lisocabtagene maraleucel||Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD)||Recruiting||11|
|NCT03744676||Phase II||Lisocabtagene maraleucel||A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Ldymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)||Active, not recruiting||USA||0|